Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSL ( (AU:CSL) ) has provided an announcement.
CSL Limited announced the issuance of 200 ordinary fully paid securities, effective November 5, 2025. This move indicates an ongoing strategy to enhance its capital structure, potentially impacting its market positioning and offering implications for stakeholders regarding the company’s financial strategies.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$225.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and manufacturing of innovative medicines and vaccines. The company is known for its work in plasma therapies, vaccines, and pharmaceuticals, serving a global market with a strong emphasis on research and development.
Average Trading Volume: 1,351,815
Technical Sentiment Signal: Sell
Current Market Cap: A$85.87B
For a thorough assessment of CSL stock, go to TipRanks’ Stock Analysis page.